The liver, a vital organ with a remarkable capacity for regeneration, plays a central role in metabolism, detoxification, and immune function. However, its complex architecture and diverse cellular composition make it challenging to study in a traditional cell culture setting. Animal models, while valuable, often fail to fully recapitulate human liver physiology and disease mechanisms. In recent years, a groundbreaking technology known as organoids has emerged, offering a powerful new platform for biological research. Liver organoids are miniature, three-dimensional (3D) cell grown in a lab that closely mimic the architecture and function of the human liver. Liver organoids are used in various fields such as drug discovery and drug toxicity assessment.
Figure 1 Shows the structural organization of the liver at different scales.1,5
Liver organoids are self-assembling, 3D multicellular structures derived from pluripotent stem cells (PSCs) or adult liver stem/progenitor cells that mimic key aspects of the native human liver's architecture and function. Unlike conventional 2D cell cultures, organoids spontaneously organize into complex structures that resemble the in vivo tissue, exhibiting cellular differentiation, intercellular interactions, and tissue-specific functions. They typically contain various liver cell types, including hepatocytes (the main functional cells of the liver), cholangiocytes (cells lining the bile ducts), and sometimes even stellate cells and endothelial cells, replicating the liver's intricate cellular diversity.
Liver organoids are self-organizing 3D structures composed of multiple liver-specific cell types, including hepatocytes, cholangiocytes (bile duct cells), and occasionally endothelial or stromal cells. They are categorized into two main types:
Simple organoids
Complex organoids
The two main methods for the generation of liver organoids are:
Liver tissue-derived organoids
These are generated from adult bile duct-derived bipotent progenitor cells, fetal hepatocytes, or surgically resected tumor tissues. The process involves isolating single liver cells and culturing them in a specific medium.
Pluripotent stem cell-derived liver organoids
These are developed from ESCs or iPSCs. Their generation involves a multi-step differentiation process, including endodermal differentiation, hepatic specification, and final hepatic maturation leading to liver organoid formation.
Figure 2 Two main methods for generation of liver organoids.2,5
Liver organoids provide invaluable in vitro models for studying various liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis (e.g., HBV, HCV), genetic liver disorders (e.g., α1-antitrypsin deficiency), and liver cancer. Researchers can introduce disease-causing mutations, expose organoids to toxins, or infect them with viruses to recapitulate disease phenotypes and investigate underlying molecular mechanisms.
Table 1. Organoid-based models of liver disease.3,5
| Disease | Species | Organoid source and derivation |
|---|---|---|
| Alagille syndrome | Human Mouse | Adult tissue (surgical resection), iPSCs (fibroblast-derived), Adult tissue (GEMM) |
| Alcohol-related liver disease | Human | ESCs |
| Alpha-1 antitrypsin deficiency | Human | Adult tissue (surgical resection; liver transplantation; biopsy) |
| Citrullinemia type I | Human | iPSCs (fibroblast-derived) |
| Cystic fibrosis | Human |
ESCs iPSCs (fibroblast-derived; peripheral blood derived) |
| HBV infection | Human | iPSCs (fibroblast-derived) |
| Primary liver cancer | Human Mouse |
Adult tissue (surgical resection) Adult tissue (needle biopsy) Adult tissue (liver transplantation; genome editing) Adult tissue (chemical carcinogenesis) Adult tissue (GEMM) |
| Primary sclerosing cholangitis | Human | Adult tissue (bile-derived; surgical resection) |
| Steatosis, steatohepatitis | Human Cat |
iPSCs (fibroblast-derived) Adult tissue (post-mortem) |
| Wilson's disease | Dog | Adult tissue (surgical resection, needle biopsy, fine needle aspiration) |
Figure 3 Various applications of liver organoids technology.4,5
Cell transplantation has achieved notable progress across various regenerative medicine applications, yet persistent hurdles remain, such as suboptimal donor material, limited engraftment rates, and the risk of immune rejection. Liver organoid transplantation represents a promising evolution of cellular therapies, offering enhanced therapeutic capabilities. Research consistently indicates that liver organoid transplantation can restore liver function in experimental animal models. For instance, transplanting vascularized human liver organoids into mice with drug-induced liver injury has been shown to successfully improve survival.
| Advantages | Disadvantages |
|---|---|
| Human-derived: Avoids species-specific biases in drug responses. | Incomplete maturation: Limited metabolic enzyme activity compared to adult hepatocytes. |
| 3D architecture: Mimics cell-cell interactions and zonation. | Lack of vascularization: Most models exclude blood vessels, affecting nutrient diffusion. |
| Scalability: Suitable for high-throughput drug screening. | Cost and complexity: Requires specialized matrices (e.g., Matrigel) and growth factors. |
| Patient-specific: Enables precision medicine for rare genetic diseases. | Standardization challenges: Variability in protocols across labs. |
Q: What's the main difference between liver organoids and traditional 2D liver cell cultures?
A: The primary difference lies in their dimensionality and complexity. 2D cultures grow cells in a flat layer on a plastic dish, lacking the natural tissue architecture. Liver organoids, however, self-assemble into complex 3D structures that mimic the liver's intricate cellular organization, allowing for more accurate cell-cell interactions and tissue-specific functions.
Q: Are liver organoids actual miniature livers? Can they replace a damaged human liver?
A: While liver organoids remarkably mimic many aspects of the human liver, they are not full miniature organs in the complete sense. They lack full vascularization (blood vessel networks), a complete immune system, and innervation, all of which are crucial for a fully functional organ in vivo. Therefore, they cannot currently replace a damaged human liver for transplantation. Their primary role is as a powerful research tool and potential stepping stone for future regenerative therapies.
Q: What are liver organoids made from?
A: Liver organoids are typically derived from two main sources:
Q: How long do liver organoids survive in culture?
A: The survival time of liver organoids in culture varies depending on the specific protocol, source cells, and culture conditions. Generally, they can be maintained for several weeks to several months, and in some advanced protocols, even longer, while retaining their functionality.
Liver organoids represent a transformative technology in the field of liver research and medicine. By providing physiologically relevant, human-specific models of liver tissue, they are significantly advancing our understanding of liver development, disease pathogenesis, and drug responses. While challenges remain, particularly regarding complete maturation, vascularization, and immune cell integration, ongoing research is rapidly addressing these limitations. The future holds immense promise for liver organoids to revolutionize drug discovery, personalize patient care, and ultimately contribute to novel therapeutic strategies for a wide range of debilitating liver diseases.
Creative Biolabs is at the forefront of biomedical innovation, offering cutting-edge liver organoid services that are transforming drug discovery, disease modeling, and regenerative medicine.
Creative Biolabs' 3D biology platforms integrate advanced cell culture techniques, microfluidics, and real-time monitoring to deliver physiologically relevant data, bridging the gap between in vitro and in vivo studies. Contact us today to learn more!
References